evipedia.ai ← Back

NanoKnife to Treat Prostate Cancer

Evidence Review created on 07/30/2026 using AI4L / Opus 4.8

Also known as: Irreversible Electroporation, IRE

Motivation

NanoKnife is the brand name for a targeted treatment that uses brief, high-voltage electrical pulses to destroy a small area of prostate cancer while leaving the rest of the gland and nearby structures intact. Thin needles placed around the tumor create permanent tiny holes in the cancer cell membranes, causing the cells to die without heat or cold. Because it treats only the diseased part of the gland, it is called a “focal” therapy.

Prostate cancer is one of the most common cancers in men, and many tumors grow slowly. The two long-standing treatments — surgery and radiation — are effective but can leave lasting effects on urinary control and sexual function. This has driven interest in gland-sparing options that treat the cancer while protecting everyday function. NanoKnife received specific clearance for prostate tissue from United States regulators in late 2024.

This review examines what is known about NanoKnife for prostate cancer: how it works, which men it may suit, and the quality and limits of the evidence for cancer control and for urinary and sexual function. It presents the case for and against the approach, including where the evidence remains uncertain.

Benefits - Risks - Protocol - Conclusion

This section lists high-level, directly relevant resources that give a broad overview of NanoKnife and focal therapy for prostate cancer.

Note: Content dedicated specifically to NanoKnife or irreversible electroporation could not be found from Rhonda Patrick, Andrew Huberman, Chris Kresser, or Life Extension; their platforms do not appear to cover this procedure, so no items from those experts are listed.

Grokipedia

  • Nanoknife

    The article describes the NanoKnife system and its use of irreversible electroporation across several organs, including a dedicated treatment of prostate cancer, its non-thermal mechanism, and function-preservation rationale. It is a useful, broad reference-style entry that links the device to the underlying ablation science.

Examine

No Examine article exists for NanoKnife or irreversible electroporation. Examine focuses on dietary supplements and nutrition and does not cover surgical devices or ablation procedures.

ConsumerLab

No ConsumerLab article exists for NanoKnife or irreversible electroporation. ConsumerLab evaluates dietary supplements and consumer health products and does not cover surgical devices or ablation procedures.

Systematic Reviews

The following are the most relevant systematic reviews and meta-analyses of irreversible electroporation (IRE) for prostate cancer identified on PubMed, prioritized by relevance, recency, and study size. Across this literature the evidence is dominated by single-arm cohorts rather than randomized comparisons, and part of the underlying research and device development is linked to the manufacturer, AngioDynamics, whose commercial interest in adoption is a source of potential bias; the surgical and radiation-oncology communities that provide the competing whole-gland treatments carry their own financial interests in the opposite direction.

Mechanism of Action

NanoKnife delivers irreversible electroporation (IRE): a series of short, high-voltage direct-current pulses passed between needle electrodes placed around the tumor. The electric field raises the voltage across each cell’s outer membrane past a critical threshold, opening permanent nanometer-scale pores. The cell can no longer maintain its internal balance of ions and water and dies, predominantly through apoptosis (an orderly, programmed form of cell death) with some necrosis (disorderly cell death) at the highest field strengths.

The defining feature is that the effect is non-thermal at the core of the treatment zone. Because heat is not the killing agent, the collagen scaffolding, larger blood vessels, nerves, and the wall of the urinary channel within the treated area are relatively spared, and this connective-tissue framework can guide regeneration. This is the mechanistic basis for the claim that NanoKnife preserves continence and erectile nerves better than heat- or freezing-based ablation.

Two mechanistic debates are relevant. First, the balance of apoptosis versus thermal injury: opponents note that at clinical settings some heating does occur near the electrodes, so the “purely non-thermal” framing is an idealization rather than an absolute. Second, there is growing interest in whether IRE releases tumor antigens in a way that provokes a local immune response (a possible “abscopal,” or distant, effect); supporters point to preclinical signals, while skeptics note this is unproven in prostate cancer.

As a device-based ablation rather than a drug, NanoKnife has no systemic pharmacological properties such as half-life, tissue distribution, or hepatic (liver) metabolism; its action is confined to the local electric field and the tissue within it.

Historical Context & Evolution

Electroporation — using electric fields to make cell membranes permeable — has been used in biology and food processing for decades, mostly in its reversible form to insert genes or drugs into temporarily opened cells. In the mid-2000s, researchers including Boris Rubinsky and Rafael Davalos characterized the irreversible threshold at which the pores never reseal and the cell dies, opening the door to using electroporation itself as a tissue-ablation tool rather than a delivery method.

AngioDynamics commercialized this as the NanoKnife system, which received United States clearance for soft-tissue ablation around 2009. The rationale for moving into the prostate was the persistent problem of overtreatment: radical prostatectomy and radiation control cancer well but carry meaningful rates of incontinence and erectile dysfunction, while active surveillance (careful monitoring without immediate treatment) leaves some men anxious and untreated. A non-thermal, nerve-sparing focal option promised a middle path, and early prostate series appeared in the early 2010s, followed by the prospective NEAT protocol.

Historically, IRE’s actual findings in the prostate have been consistently favorable for function preservation and short-term cancer control, but the research has been dominated by single-arm cohorts. Rather than being “debunked” or “proven,” the technique is best described as promising but incompletely validated. The clearest recent shift was the manufacturer-sponsored PRESERVE pivotal study, which supported a specific United States regulatory clearance for prostate tissue ablation in December 2024 — a change that reflects new prospective safety and biopsy data, not settled long-term comparative evidence, and that carries the manufacturer’s commercial interest.

Expected Benefits

The benefits below are framed for risk-aware, proactive men with early localized disease who are specifically weighing gland-sparing treatment against whole-gland surgery, radiation, or active monitoring — a group for whom preserving urinary and sexual function while controlling cancer is a central goal. A dedicated search of the systematic-review and expert literature was performed to confirm the benefit profile is complete before writing this section.

High 🟩 🟩 🟩

None of the benefits reach the High evidence tier, because there are currently no randomized controlled trials (studies that randomly assign men to NanoKnife versus an established treatment) directly comparing NanoKnife against surgery, radiation, or surveillance.

Medium 🟩 🟩

Short- to Intermediate-Term In-Field Cancer Control

Across multiple prospective and retrospective cohorts and pooled analyses, NanoKnife eliminates clinically significant cancer within the treated zone in the large majority of men, with failure-free survival holding up over 3 years. The evidence is consistent but non-comparative and follow-up is short, so this is graded Medium rather than High. Control of cancer outside the treated area depends heavily on patient selection.

Magnitude: In-field clinically significant cancer 0%–15.6% on follow-up biopsy; 3-year failure-free survival 90%–96.8%.

Preservation of Urinary Continence

Continence outcomes are the most reproducible benefit: nearly all treated men remain pad-free, and pooled analyses report a low urinary-function impact in roughly 97% of cases. The proposed mechanism is sparing of the external sphincter and bladder neck because the ablation is non-thermal and focal. Consistency across many cohorts and a meta-analysis supports a Medium grade, limited only by the absence of randomized comparison.

Magnitude: Pad-free rate 96.7%–100%; ~97% report low urinary impact in pooled analysis.

Preservation of Erectile Function ⚠️ Conflicted

Many series report that erections sufficient for intercourse return toward baseline by 6–12 months, attributed to relative sparing of the neurovascular bundles. However, results are markedly heterogeneous between studies, with some cohorts showing meaningful and lasting decline, so the evidence is directly conflicted. Differences in patient age, baseline function, unilateral versus bilateral treatment, and how potency is measured likely explain the discrepancy.

Magnitude: Potency preservation ranges roughly 44%–100% at 12 months across cohorts (highly heterogeneous).

Low 🟩

Metastasis-Free and Cancer-Specific Survival (Short-Term)

Pooled survival figures are very high, but they are drawn from short-follow-up, single-arm data in men who mostly had low- or intermediate-risk disease with an inherently good prognosis, so lead-time and selection strongly inflate the apparent benefit. This is graded Low despite the high headline numbers because the data cannot yet distinguish the treatment’s effect from the favorable natural history.

Magnitude: Pooled cancer-specific survival ~97.9%–99.3%; metastasis-free survival ~98.5%–99.1% at short-term follow-up.

Preservation of Ejaculatory Function

Because much of the gland and its ducts are left intact, many men retain some antegrade ejaculation, unlike after radical prostatectomy where it is lost. The evidence is limited and inconsistently measured, so the grade is Low.

Magnitude: Not quantified in available studies.

Preservation of Future Treatment Options

NanoKnife does not preclude later definitive treatment: salvage radical prostatectomy or radiation remain technically feasible if cancer recurs or progresses, and the ablation can sometimes be repeated. This flexibility is a genuine advantage over whole-gland therapy, though retreatment rates are non-trivial and salvage surgery after any focal therapy is more difficult than primary surgery.

Magnitude: Retreatment rate 8%–36.6%; salvage prostatectomy and radiation remain technically feasible.

Speculative 🟨

Local Immunomodulation (Abscopal Potential)

There is preclinical and early mechanistic interest in whether the non-thermal release of tumor antigens by IRE could stimulate an anti-tumor immune response reaching beyond the treated field. In prostate cancer this remains hypothetical, with no controlled human data demonstrating a clinically meaningful immune benefit; the basis is mechanistic and anecdotal only.

Benefit-Modifying Factors

  • Germline and tumor genetics: Men carrying aggressive-disease mutations such as BRCA2 (a DNA-repair gene whose loss raises cancer aggressiveness), BRCA1, or ATM tend to have higher-grade, faster-progressing cancer, which can reduce the durability of any focal treatment and may argue against NanoKnife in favor of whole-gland therapy.

  • Baseline biomarker and pathology levels: Lower pre-treatment PSA, low PSA density, a single well-defined lesion, Grade Group 1–2 disease (a low-to-intermediate aggressiveness score), and a clearly visible target on imaging all predict greater benefit; higher values predict earlier recurrence and out-of-field disease.

  • Sex-based considerations: Prostate cancer occurs in people with a prostate (males and some transgender women); there is no cross-sex comparison to make, but hormonal status — for example concurrent estrogen therapy or low testosterone — can influence gland size and disease behavior and thus the expected benefit.

  • Pre-existing health conditions: A smaller, calcification-free gland and no prior transurethral resection favor complete, well-targeted ablation and therefore greater benefit; large glands and heavy calcification make full tumor coverage harder.

  • Age-related considerations: Younger men with long life expectancy gain the most from function preservation but also have the most years in which an under-treated cancer could progress; older men at the upper end of the target range may derive less incremental benefit over active surveillance if their cancer is low-risk.

Potential Risks & Side Effects

The risks below are framed for the same proactive, function-focused audience and were cross-checked against drug- and device-safety references, prescribing-style safety summaries, and the systematic-review literature to confirm completeness.

High 🟥 🟥 🟥

Transient Lower Urinary and Genital Symptoms

Most men experience temporary urinary burning, frequency, urgency, blood in the urine (hematuria), and blood in the semen (hematospermia) in the first days to weeks, reflecting local tissue injury and healing. These are expected, self-limiting effects rather than complications and are consistently reported across cohorts. Severity is generally mild and resolves without intervention.

Magnitude: Clavien-Dindo grade I–II events in roughly 5%–20%; most symptoms resolve within 4–6 weeks.

Erectile Dysfunction ⚠️ Conflicted

A decline in erectile function is common in the first one to three months even when nerve-sparing is intended, because the ablation field and post-procedure inflammation affect the adjacent neurovascular bundles. Whether this fully recovers is genuinely conflicted in the literature: many cohorts show recovery toward baseline by 6–12 months, while others report persistent dysfunction, with differences driven by age, baseline function, and treatment extent.

Magnitude: Erectile function commonly declines in the first 1–3 months, with recovery toward baseline by 6–12 months in a majority and persistent dysfunction in a minority.

Medium 🟥 🟥

Urinary Tract Infection and Acute Urinary Retention

Urinary tract infection is the single most frequently reported complication, and some men cannot urinate immediately after catheter removal because of swelling, requiring temporary recatheterization. Both are managed with standard care (antibiotics, short-term catheterization). The evidence base for these events is reasonably consistent across prospective series.

Magnitude: Urinary tract infection is the most frequently reported complication; acute retention in roughly 2%–5%.

Treatment Failure and Recurrence Requiring Retreatment

Cancer can persist or recur within the treated zone (in-field) or appear elsewhere in the gland (out-of-field), leading to a further ablation, surgery, or radiation. This is an inherent limitation of treating only part of the gland and of short follow-up, and rates vary widely with patient selection and how recurrence is defined. It is the most important oncological downside of the focal approach.

Magnitude: In-field recurrence 0%–15.6%; out-of-field recurrence 3.6%–28%; retreatment 8%–36.6%.

Low 🟥

Rectourethral Fistula and Rectal Injury

A rare but serious complication is an abnormal connection between the urinary channel and the rectum, or direct rectal injury, when the ablation is near the back of the gland. It can require major reconstructive surgery. Reported rates are very low, and careful electrode placement and imaging reduce the risk further.

Magnitude: Rectourethral fistula is rare (<1%).

Urethral Stricture or Bladder Neck Contracture

Scarring can narrow the urinary channel or bladder outlet, causing a weak stream or obstruction that may need dilation or a minor procedure. This is uncommon because the non-thermal mechanism tends to spare the channel wall, but it is not eliminated. Prior prostate surgery increases the risk.

Magnitude: Urethral stricture or bladder neck contracture in roughly 1%–3%.

Because the pulses are electrical, they can theoretically trigger an irregular heartbeat; this is why treatment is synchronized to the electrocardiogram (ECG, a recording of the heart’s rhythm). With synchronization the risk is low, but transient arrhythmia has been reported, and men with existing conduction problems are at higher risk.

Magnitude: Rare with ECG-synchronized pulsing; transient arrhythmia reported in isolated cases.

Speculative 🟨

Long-Term Oncologic Failure from Understaging or Undertreatment

Because follow-up is mostly short and biopsy sampling is imperfect, there is a theoretical concern that some men harbor missed higher-grade or multifocal disease that will surface as clinically significant progression years later. This is a plausible risk grounded in the immaturity of long-term comparative data rather than a demonstrated rate, and it is the main reason durable oncologic value remains unsettled.

Risk-Modifying Factors

  • Genetic and tumor-biology factors: Aggressive-disease mutations (for example BRCA2 or ATM) and higher Grade Group disease raise the chance of oncologic failure after focal treatment, effectively increasing the risk that NanoKnife under-treats the cancer.

  • Baseline biomarker levels: High PSA, high PSA density, and large or multifocal tumor volume increase the likelihood of residual or recurrent disease and therefore of needing further treatment.

  • Sex-based differences: As a male-only disease there is no cross-sex risk comparison, but hormonal status affecting gland size and vascularity can modify procedural risk (for example bleeding and completeness of ablation).

  • Pre-existing health conditions: Cardiac conduction disorders or an implanted pacemaker or defibrillator raise the arrhythmia risk; prior transurethral resection, a very large gland, or a lesion abutting the rectum raises the risk of retention, stricture, and rectal injury; bleeding disorders and anticoagulation raise bleeding risk.

  • Age-related considerations: Older men more often have baseline erectile and urinary impairment and more cardiac comorbidity, so both functional side effects and procedural risk tend to be higher at the upper end of the target range.

Key Interactions & Contraindications

NanoKnife is a procedure performed under general anesthesia, so the relevant “interactions” are peri-procedural drug and device considerations rather than ongoing pharmacology.

  • Prescription drug considerations: Anticoagulants (blood thinners such as warfarin, apixaban, rivaroxaban) and antiplatelet agents (aspirin, clopidogrel) must usually be paused before treatment — severity: caution to temporary contraindication; consequence: bleeding and hematoma. Drugs that prolong the heart’s QT interval or provoke arrhythmia warrant review with anesthesia — severity: caution; consequence: increased peri-procedural arrhythmia risk.

  • Over-the-counter medication considerations: Over-the-counter nonsteroidal anti-inflammatory drugs (for example ibuprofen, naproxen) and aspirin increase bleeding risk and are typically held before the procedure — severity: caution; consequence: bleeding.

  • Supplement interactions: Supplements with blood-thinning or antiplatelet effects (fish oil / omega-3, vitamin E, ginkgo, garlic, high-dose curcumin) should be stopped before treatment — severity: caution; consequence: increased bleeding.

  • Additive-effect supplements and agents: Any agent that adds to bleeding risk (the supplements above together with prescription anticoagulants) is additive and should be reconciled as a group before surgery — severity: caution; consequence: compounded bleeding risk.

  • Other intervention interactions: Prior or planned radiation, hormone therapy (androgen deprivation therapy, ADT, which lowers testosterone), or previous transurethral resection alter anatomy and healing and must be factored into planning — severity: caution; consequence: altered ablation completeness and higher complication risk.

  • Populations who should avoid the intervention: High-risk or locally advanced disease (Grade Group ≥ 4, equivalent to Gleason ≥ 8), PSA > 20 ng/mL, clinical stage ≥ cT3 with spread beyond the capsule, or any metastatic disease; men with a cardiac implantable electronic device (pacemaker or defibrillator) or significant arrhythmia; men unfit for general anesthesia; and glands with heavy calcification or very large volume that prevent complete, safe ablation.

  • Severity and thresholds: These exclusions are defined by specific classifications rather than general categories — for example Grade Group ≥ 4, PSA > 20 ng/mL, stage ≥ cT3, presence of any cardiac implantable electronic device, or metastatic (spread) disease.

Risk Mitigation Strategies

  • Rigorous patient selection with imaging and mapping biopsy: Confirm a single, well-localized, imaging-visible target using multiparametric magnetic resonance imaging (mpMRI, detailed scans combining several sequences) plus template or fusion biopsy before treating — this mitigates the central risk of under-treating occult higher-grade or multifocal cancer.

  • Electrocardiogram synchronization: Time every pulse to the heart’s cycle using ECG gating — this mitigates the risk of procedure-related cardiac arrhythmia.

  • Deep neuromuscular blockade under general anesthesia: Fully relax the muscles so the electrical pulses do not cause violent contractions — this mitigates electrode displacement, tissue tearing, and injury to adjacent structures.

  • Adequate ablation margins and accurate electrode spacing: Place electrodes 1–2 cm apart and cover the tumor plus a margin — this mitigates in-field recurrence from incomplete kill.

  • Peri-procedural medication management: Stop anticoagulants, antiplatelets, and bleeding-promoting supplements on the schedule advised by the care team, and give antibiotic prophylaxis — this mitigates bleeding and urinary tract infection.

  • Posterior-margin caution near the rectum and short-term catheterization: Respect a safe distance from the rectal wall and place a temporary catheter — this mitigates rectourethral fistula, rectal injury, and acute urinary retention.

  • High-volume operator and mandatory follow-up biopsy: Choose an experienced center and commit to a scheduled in-field biopsy at 12 months — this mitigates the risk that recurrence goes undetected until it is advanced.

Therapeutic Protocol

  • Standard approach used by leading practitioners: As described by high-volume focal-therapy groups (for example Stricker in Sydney, de la Rosette and colleagues internationally, and the London focal-therapy programs behind the NEAT protocol), treatment follows mpMRI and targeted plus systematic biopsy to confirm a suitable target, then transperineal placement of needle electrodes around the lesion under general anesthesia with full muscle relaxation and ECG-synchronized pulsing.

  • Procedure parameters: Multiple short high-voltage pulses (broadly in the ~1,500 V range, delivered in trains of dozens of pulses) are passed between paired electrodes spaced roughly 1–2 cm apart, with placement and coverage guided by ultrasound and the treatment-planning software.

  • Competing therapeutic approaches: The main alternatives are presented without defaulting to one — heat-based HIFU and freezing-based cryotherapy among focal options, and whole-gland radical prostatectomy, radiation therapy, and active surveillance among standard options; pooled data show broadly similar short-term outcomes across the focal modalities, and the choice depends on tumor location, gland features, and operator expertise.

  • Extent of ablation: A further live debate is focal (lesion-only) versus extended or hemi-gland ablation; wider treatment may lower in-field recurrence at some cost to function, and no approach is established as clearly superior.

  • Best timing: As a one-time procedure there is no time-of-day dosing; scheduling is driven by anesthesia fitness, cessation of blood thinners, and resolution of any active urinary infection.

  • Genetic factors influencing the choice: Carriers of aggressive-disease mutations (BRCA2, ATM) may be steered away from a gland-sparing approach toward whole-gland treatment because of higher recurrence risk.

  • Sex-based differences: The protocol applies to people with a prostate; there is no female-dosing comparison, though hormonal status affecting gland size is considered in planning.

  • Age-related considerations: Older men are assessed for anesthesia fitness and competing life expectancy; very low-risk older men may be better served by surveillance.

  • Baseline biomarkers influencing response: Pre-treatment PSA, PSA density, Grade Group, and lesion size guide both candidacy and the extent of ablation.

  • Pre-existing conditions influencing response: Gland size, calcification, prior transurethral resection, and cardiac status shape feasibility and technique.

Discontinuation & Cycling

  • One-time versus ongoing treatment: NanoKnife is delivered as a single focal procedure, not an ongoing therapy, so there is no daily regimen to stop or continue; the ongoing element is active surveillance of the rest of the gland afterward.

  • Withdrawal effects: There are no withdrawal effects, because nothing is taken continuously; post-procedure symptoms are healing-related and self-limiting rather than withdrawal phenomena.

  • Tapering: No tapering applies, as there is no maintenance medication to reduce gradually.

  • Repeat treatment (“cycling”): Rather than cycling for efficacy, a repeat ablation is considered only if surveillance detects persistent or recurrent in-field disease; some men undergo a second NanoKnife, while others move to surgery or radiation.

  • Post-treatment surveillance commitment: Because the gland remains, lifelong monitoring with PSA and periodic imaging and biopsy is an essential ongoing consideration after the single procedure.

Sourcing and Quality

Source, purity, and formulation criteria do not apply to a surgical device, so this section is reframed around choosing the system and the provider; the underlying supplement-style sourcing considerations are not applicable.

  • Use of the cleared device and platform: Confirm treatment uses the AngioDynamics NanoKnife system with current-generation electrodes and treatment-planning software, ideally under the specific regulatory clearance for prostate tissue rather than purely off-label use.

  • Operator and center selection: Prioritize high-volume centers and urologists formally trained and proctored on prostate IRE, since outcomes for all focal therapies are operator-dependent.

  • Image guidance quality: Ensure the workflow uses good-quality mpMRI and MRI-ultrasound fusion or transperineal template mapping, which underpins accurate targeting and margins.

  • Verification of candidacy and reporting: Look for centers that adhere to consensus reporting and mandate follow-up biopsy, so cancer control is measured rather than assumed.

Practical Considerations

  • Time to effect: The ablation is immediate, but cancer control is not confirmed until follow-up — PSA typically settles to a new lower baseline over about 3–6 months, and the key oncologic assessment is the in-field biopsy at around 12 months.

  • Common pitfalls: The most common mistakes are poor patient selection (treating high-risk or multifocal disease), inadequate margins, relying on PSA alone instead of biopsy to judge success, and skipping scheduled surveillance.

  • Regulatory status: In the United States the NanoKnife system received a specific 510(k) clearance for prostate tissue ablation in December 2024; before that, prostate use was largely off-label under a general soft-tissue clearance, and regulatory status varies by country.

  • Cost and accessibility: NanoKnife is expensive, offered at a limited number of specialized centers, and frequently not reimbursed by insurers or national health systems, so many men pay out of pocket — a structural factor that also gives payers a financial reason to favor cheaper active surveillance or established whole-gland treatments over newer focal therapy.

  • Recovery logistics: Treatment is usually day-case or one overnight stay with a temporary urinary catheter for one to a few days and a short recovery before return to normal activity.

Interaction with Foundational Habits

  • Sleep: Indirect interaction. The procedure does not directly disrupt sleep, but post-treatment urinary frequency and the anxiety of cancer surveillance can impair it in the short term; prioritizing sleep supports general recovery and immune function. Practical point: expect temporary nighttime urination while healing.

  • Nutrition: Indirect interaction. No specific diet enhances or blunts the ablation, but bleeding-promoting supplements (fish oil, vitamin E, high-dose curcumin, garlic, ginkgo) should be paused peri-procedurally, and an overall prostate-healthy dietary pattern supports long-term disease management. Practical point: reconcile all supplements with the care team before treatment.

  • Exercise: Indirect, potentiating for recovery. Strenuous activity and cycling are usually avoided for a short period after treatment to limit bleeding and discomfort, while pelvic-floor exercises can aid recovery of urinary control. Practical point: resume graded activity as advised, and consider pelvic-floor training.

  • Stress management: Indirect interaction. NanoKnife does not act on the stress hormone system, but treatment and ongoing surveillance are psychologically demanding, and some cohorts have reported mild anxiety and insomnia during follow-up; stress-reduction practices support adherence to monitoring. Practical point: build in psychological support around the surveillance schedule.

Monitoring Protocol & Defining Success

Before treatment, a baseline workup establishes the cancer’s extent and the man’s function so that later change can be measured; this includes PSA and PSA density, mpMRI, targeted plus systematic biopsy to define grade and location, testosterone, and baseline questionnaires for urinary and sexual function. Ongoing monitoring then follows a defined cadence: PSA every 3 months for the first year and every 6 months thereafter, mpMRI at 6–12 months, a mandatory in-field biopsy at around 12 months, and periodic imaging and biopsy afterward for as long as the gland remains.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
PSA (prostate-specific antigen) Stable low nadir; no confirmed rise > ~2 ng/mL above nadir Tracks residual or recurrent cancer activity Will not fall to zero because gland remains; avoid ejaculation, cycling, and digital rectal exam for 48 h before the draw; no fasting needed
PSA nadir Reached by ~3–6 months post-treatment A higher or rising nadir signals possible in-field failure Interpret as a trend over serial tests, not a single value
PSA density (PSA ÷ gland volume) Lower is better; trend down or stable Adjusts PSA for gland size to improve recurrence detection Requires gland volume from mpMRI or ultrasound
Testosterone (total) Age-appropriate mid-normal (~400–700 ng/dL) Confirms PSA is not artificially suppressed by low testosterone or hormone therapy Draw in the morning; flags occult androgen deprivation that would confound PSA

Qualitative markers are tracked alongside the labs to judge whether function is being preserved:

  • Urinary continence (pads used per day and leakage episodes)
  • Lower urinary tract symptoms (stream strength, urgency, frequency, nighttime urination)
  • Erectile function (erections sufficient for intercourse, with or without medication)
  • Ejaculatory function (presence and volume of ejaculate)
  • Energy, mood, and treatment-related anxiety or sleep disturbance

Emerging Research

Research framed for proactive men weighing this option is moving from single-arm cohorts toward comparative and function-focused trials that will determine NanoKnife’s long-term standing.

  • Pivotal regulatory trial (PRESERVE): The manufacturer-sponsored study behind the 2024 United States clearance, evaluating negative in-field biopsy and device-related adverse events at 12 months in intermediate-risk disease (NCT04972097; completed; 121 participants; sponsor AngioDynamics — a direct commercial interest to note).

  • Investigator-initiated focal IRE trial (Pan-Canadian): A multicentre study directed at intermediate-risk prostate cancer with a primary endpoint of negative in-field biopsy at 12 months and adverse-event capture (NCT06451445; recruiting; 100 participants; University Health Network, Toronto).

  • Function-focused cohort (PRIS): A study centered on urinary continence and irritative urinary symptoms after prostate IRE (NCT05513443; recruiting; 184 participants; Karolinska Institutet).

  • Combination with radiation (RTIRE): A study combining radiation therapy and IRE for intermediate-risk disease, assessing feasibility and cancer-free status (NCT05345444; active, not recruiting; 48 participants; Weill Cornell).

  • Head-to-head against surgery (H-FIRE): A planned comparison of high-frequency IRE against laparoscopic radical prostatectomy focused on urinary and sexual function (NCT04278261; not yet recruiting; 216 participants; Shanghai East Hospital).

  • Future directions — long-term and comparative evidence: The dominant gap is the lack of randomized comparison and long follow-up; meta-analysts have made this the central call, with Guo et al., 2021 explicitly urging larger randomized controlled trials (PubMed) and Tay et al., 2025 urging standardized long-term outcome reporting (PubMed). Evidence could cut either way — durable oncologic control and function preservation would strengthen the case, while long-term recurrence or under-treatment signals would weaken it.

  • Future directions — biology and immune effects: Whether IRE meaningfully engages the immune system in prostate cancer is an open question that current work is beginning to probe, and a positive signal would reframe the technique beyond local ablation.

Conclusion

NanoKnife is a gland-sparing way to treat prostate cancer that uses short bursts of electricity to destroy a targeted area of tumor while trying to protect the nerves, the urinary channel, and the muscles that control urination and erections. For men with early, localized disease who hope to avoid the lasting urinary and sexual effects that can follow whole-gland surgery or radiation, it represents a middle path between simply monitoring the cancer and treating the entire prostate. The available evidence suggests it controls cancer well over the short and medium term and preserves urinary control in nearly all men, with more variable effects on sexual function.

The evidence base, however, is still young and carries real limits. Almost all studies follow a single group of treated men rather than directly comparing NanoKnife against surgery, radiation, or monitoring, and most follow men for only a few years, so its long-term cancer results are not yet clear. Much of the research and the device itself have been funded or shaped by the company that manufactures it, while surgeons and radiation specialists carry their own financial reasons to favor the treatments they already provide; these competing interests are relevant when weighing the published findings. Overall, NanoKnife appears to be a promising, function-preserving option whose long-term standing remains unsettled.

Top - Benefits - Risks - Protocol